News Releases

Month Year

Month Year

Investor Alerts

Jan 23, 2023

IDEAYA Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma
Jan 9, 2023

IDEAYA Announces IND Clearance by U.S. FDA enabling Phase 1 Initiation for First-in-Class PARG Development Candidate IDE161
Jan 3, 2023

IDEAYA Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
Dec 19, 2022

IDEAYA Biosciences Appoints Dr. Karlene Cimprich, Ph.D. and Dr. Kornelia Polyak, M.D., Ph.D. to Scientific Advisory Board
Dec 12, 2022

IDEAYA Biosciences Announces Submission of IND Application to the U.S. FDA for PARG Development Candidate IDE161
Dec 5, 2022

IDEAYA Biosciences Receives Fast Track Designation for Darovasertib Combination Therapy with Crizotinib for the Treatment of Metastatic Uveal Melanoma
Nov 29, 2022

IDEAYA Biosciences Announces Agenda Topics and Key Opinion Leader Presenters for Investor R&D Day Webcast on Monday, December 12, 2022
Nov 28, 2022

IDEAYA Biosciences Appoints Darrin M. Beaupre, M.D., Ph.D., as Chief Medical Officer to Lead Clinical Development of Expanding Clinical Pipeline
Nov 8, 2022

IDEAYA Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
Nov 1, 2022

IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Upcoming Investor Conferences
Oct 18, 2022

IDEAYA Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First-Patient-In for Multiple Combination Cohorts in MTAP-Deletion Tumors
Sep 19, 2022

IDEAYA Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Sep 14, 2022

IDEAYA Announces Pricing of Public Offering of Common Stock
Sep 14, 2022

IDEAYA Announces Proposed Public Offering of Common Stock
Sep 11, 2022

IDEAYA Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma
Sep 6, 2022

IDEAYA Announces First-Patient-In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in (Neo)Adjuvant Uveal Melanoma
Aug 30, 2022

IDEAYA Biosciences to Participate in Investor Conferences in September 2022
Aug 29, 2022

IDEAYA Announces Achievement of First Milestone in Ongoing Collaboration with GSK for Potential First-in-Class Pol Theta Helicase Inhibitor Development Candidate
Aug 15, 2022

IDEAYA Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update
Jul 27, 2022

IDEAYA Announces IDE397 Clinical Program Update and ctDNA Molecular Responses Demonstrating Tumor Pharmacodynamic Modulation
Jul 27, 2022

IDEAYA Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors
Jun 28, 2022

IDEAYA Announces Development Candidate Nomination of a Potential First-in-Class Pol Theta Helicase Inhibitor in Collaboration with GSK
Jun 8, 2022

IDEAYA Biosciences to Present at the 2022 Jefferies Global Healthcare Conference
May 10, 2022

IDEAYA Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
May 3, 2022

IDEAYA Biosciences to Participate in Investor Conferences in May 2022

Show per page